Stramsen Biotech (an emerging leader in plant-based biopharmaceutical industry) announced that it has signed a binding agreement with GEM Global Yield (GGY), part of GEM, a Luxembourg-based private alternative investment group as its Lead Investor, for a $25 million share subscription facility to be funded annually over a 36-month term following a public listing of the Stramsen’s common stock.
The funds secured through the share subscription facility will be strategically utilized to accelerate Stramsen’s growth trajectory, propel clinical development, and recruit seasoned management and scientific teams.
Stramsen will control the timing and maximum amount of drawdowns under this facility and has no minimum drawdown obligation.
The $25 million facility from GGY will significantly support Stramsen Biotech Inc.’s ambitious growth plans and empower the company to:
– Accelerate global expansion initiatives, positioning Stramsen as a leader in plant-based biopharmaceuticals.
– Prepare for prospectus submission and ultimately pursue an Initial Public Offering (IPO), which would enhance the company’s financial position and market visibility.
– Invest in research and development of 33 innovative drug candidates, leveraging our natural plant-based approach to transform patient lives.
– Initiate submitting multiple Investigational New Drug (IND) applications with the Food and Drug Administration (FDA), advancing our pipeline towards clinical trials.
– Establish a distinguished Scientific Advisory Board and expand our team of seasoned scientists, reinforcing our expertise and leadership in the industry.
KEY QUOTE:
“This commitment from GEM validates Stramsen Biotech’s vision of providing nature-based, sustainable, and affordable health solutions with minimal side effects to patients worldwide.”
- Scott Villwock, President and Chief Executive Officer of Stramsen Biotech
